MediciNova (NASDAQ:MNOV) announces an agreement to jointly develop a SARS-CoV-2 vaccine with BC-PIV, a human parainfluenza virus type 2 vector being developed by BioComo and Mie University.
The company has been granted exclusive worldwide development rights to use BC-PIV for COVID-19 vaccine development.
To date, BioComo has succeeded in producing a recombinant Ebola virus vaccine and a Respiratory Syncytial virus prefusion F vaccine using this BC-PIV platform technology.
Financial terms are not disclosed.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.